Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Clovis

- PMLiVE

Roche pharma sales strong for first half of 2015

New and old cancer drugs boost revenue for the Swiss pharma firm

- PMLiVE

Keytruda cleared for melanoma in Europe

Merck’s new PD-1 drug will compete against rival BMS for market share

- PMLiVE

NHS England proposes handing CDF remit to NICE

Comes after a difficult two years for the silo budget

Bristol-Myers Squibb (BMS) building

Opdivo gets EU lung cancer nod as kidney cancer trial is halted

Bristol-MyersSquibb's checkpoint inhibitor gains European license for lung cancer

- PMLiVE

Amgen’s Blincyto effective in broader leukaemia population

Could lead to further licences for the $178,000 blood cancer treatment

Bristol-Myers Squibb (BMS) building

BMS’ HIV combination Evotaz cleared in Europe

Comes after the firm recently announced it would shelve much of its virology unit

Celgene building

Celgene spends $7.2bn on Receptos purchase

Latest deal forms part of a major spending spree for the firm

AstraZeneca AZ

Iressa set for US market return after FDA approval

AstraZeneca'slung cancer drug wins green light for EGFR tumours

Roche Basel Switzerland

Roche’s breakthrough PD-L1 drug slows cancer growth

Latest positive trial for the firm’s next-gen oncology product atezolizumab

Celgene building

Celgene and Juno announce ten-year cancer deal

The firms’ pact will focus on the new area of immunotherapy

- PMLiVE

Opdivo approved via UK’s early drug access scheme

Bristol-Myers Squibb’s immunotherapy the first lung cancer drug approved by EAMS

Eli Lilly HQ

Lilly and Immunocore ink immunotherapy R&D deal

Firms will test new joint therapy in patients with melanoma

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links